Amneal Pharmaceuticals Exceeds Q2 Earnings and Revenue Estimates
Amneal Pharmaceuticals (AMRX) reported better-than-expected financial results for its second-quarter fiscal year 2026. The company's non-GAAP earnings per share came in at $0.30, surpassing estimates by $0.07. Additionally, revenue reached $796 million, a 9.8% increase from the previous year and exceeding forecasts by over $25 million. Amneal also reported adjusted EBITDA of $206 million for Q2 FY26, reflecting a 12% growth compared to the same period in FY25. The company used these strong results as a basis to raise its full-year fiscal 2026 outlook.
Tickers: $AMRX
Topics: Earnings Pharmaceuticals